Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.

What Was Tested

The paper reports a study of Omeprazole and Antacids, published as a randomized controlled trial.

To determine the effect of the concurrent administration of Maalox and omeprazole in the bioavailability of trovafloxacin (CP-99,219), an open, placebo-controlled, randomized, four-way crossover study was conducted in 12 healthy male volunteers.

Why It Was Studied

For treatments A and C, Maalox was also given at 22.00 h the night before the study day, 1 and 3 h after meals and at bedtime on the study day.

For B and D, placebo and omeprazole, respectively, were also given at 22.00 h the night before the study day.

Who Took Part

The study group was 12 volunteers.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Omeprazole and who got the comparison, which limits bias.

Some volunteers received a placebo instead of Omeprazole, giving a reference point.

Each person switched between Omeprazole and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Aluminum Hydroxide, Antacids, Anti-Infective Agents, Area Under Curve, Biological Availability, Drug Combinations and Fluoroquinolones.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Omeprazole and Antacids in 12 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (The Journal of antimicrobial chemotherapy), a journal based in England.

More context: all human trials.